two clinical studies have shown it may improve glycemic control and decrease insulin resistance in people with poorly controlled type 2 diabetes however servier is suspected of having marketed mediator benfluorex at odds with the drug s medical properties on 18 december 2009 the european medicines agency recommended the withdrawal of all medicines containing benfluorex in the european union because their risks particularly the risk of heart valve disease fenfluramine like cardiovascular side effects are greater than their benefits thus frachon et al showed a significantly higher prevalence of unexplained valvular heart disease in patients taking benfluorex compared to controls and weill et al looked at over 1 million diabetic patients demonstrating a higher hospitalization rate in benfluorex takers for valvular heart disease in france the medication had been marketed as by servier as an adjuvant antidiabetic under the name mediator the drug was on the market between 1976 and 2009 and is thought to have caused between 500 and 2 000 deaths the drug was also used in spain portugal and cyprus fenfluramine a related drug had been withdrawn from the market in 1997 after reports of heart valve disease pulmonary hypertension and development of cardiac fibrosis this side